The FDA has authorized Pfizer vaccination against COVID-19 between the ages of 5 and 11 years
Read Time:4 Minute, 3 Second
The U.S. Food and Drug Administration has authorized the emergency use of a booster dose of the COVID-19 Pfizer / BioNTech vaccine for children ages 5 to 11 at least five months after the completion of a series of primary vaccines. Pfizer requested this EUA in late April, citing company data that showed that the third dose of the vaccine increased the level of antibodies that fight omicron, 36 times in this age group. “Although it was mostly the case that COVID-19 tended to be less severe in children than in adults, the Omicron wave has seen more children who have had the disease and been hospitalized, and children may also experience long-term effects, even after initial lung disease, ”FDA Commissioner Dr. Robert Calif said in a press release Tuesday. “The FDA allows the use of a single booster dose of Pfizer-BioNTech’s COVID-19 vaccine for children ages 5 to 11 to provide long-term protection against COVID-19. A study by the New York State Department of Health and the U.S. Centers for Disease Control and Prevention found that the effectiveness of two doses of Pfizer vaccine for children ages 5 to 12 was significantly reduced during the amicron spike, falling from 68% to about 12% against infections. However, two doses continued to provide protection against a more severe illness that led to immediate care or hospitalization. Public health officials urged Americans to stay abreast of their vaccinations against COVID-19, including all recommended recommended doses, as the best way to protect themselves and others. A recent CNN analysis CDC data showed that for those who were fully vaccinated and reinforced in February, the risk of death from COVID-19 was 20 times lower than for unvaccinated people 1 2 and older. The CDC Immunization Practices Advisory Committee will meet Thursday to discuss means to boost vaccines against COVID-19. Although the agenda of the meeting has not been published, the vote is scheduled, according to the Federal Register. Tuesday’s ruling means anyone who is 5 years of age or older is now eligible for at least one regulatory dose. who have certain types of immunocompromise are eligible for two booster doses.Moderna has also requested FDA approval for re-vaccination from COVID-19 for anyone aged 18 and older, but a decision on that request has not yet been made.
The U.S. Food and Drug Administration has authorized the emergency use of Pfizer / BioNTech’s booster dose of COVID-19 vaccine for children ages 5 to 11 at least five months after the end of the primary vaccine series.
Pfizer asked this EUA in late April, citing company data that showed that the third dose of the vaccine increases the level of antibodies that fight omicrons by 36 times in this age group.
“While it has mostly been the case that COVID-19 tends to be less severe in children than in adults, the Omicron wave has resulted in more children contracting the disease and being hospitalized, and children may also experience long-term effects, even after an initial mild illness, ”said FDA Commissioner Dr. Robert Calif in a news release Tuesday. “The FDA allows the use of a single booster dose of Pfizer-BioNTech vaccine against COVID-19 for children aged 5 to 11 years to provide long-term protection against COVID-19.
A study by the New York Department of Health and the U.S. Centers for Disease Control and Prevention found that the effectiveness of two doses of Pfizer vaccine for children ages 5 to 12 was significantly reduced during the omicron outbreak, falling from 68% to about 12% against infection. However, the two doses continued to provide protection against more serious illnesses that led to emergency care or hospitalization.
Public health officials urged Americans to stay abreast of their vaccinations against COVID-19, including all recommended recommended doses, as the best way to protect themselves and others.
A recent analysis of CNN’s CDC data showed that for those who were fully vaccinated and reinforced in February, the risk of death from COVID-19 was 20 times lower than for unvaccinated people 12 years of age and older.
The CDC Immunization Practices Advisory Committee will meet Thursday to discuss stimulants of the COVID-19 vaccine. Although the agenda has not been published, the vote is scheduled, according to the Federal Register.
The decision, made Tuesday, means that anyone over the age of 5 is now entitled to at least one booster dose.
Those 50 years and older and people 12 years and older who have certain types of immunocompromise are eligible for two booster doses.
Moderna has also requested FDA approval for re-vaccination from COVID-19 for anyone over the age of 18, but a decision on the request has not yet been made.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
